<http://example.org/entity/#KiadisPharmaN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'Kiadis Pharma N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> 'Netherlands)'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/Exchange> 'EuronextAmsterdamN.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/Exchange> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesIdentification/InternationalSecuritiesIdentificationNumber> 'NL0011323407'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/hasExecutionDate> '2018-03-12'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://wikidata.org/entity/Q1337875> 'Intellectual property rights of third parties could adversely affect Kiadis ability tocommercialise its products.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/WorkingCapitalPurpose> 'At the Registration Document Date Kiadis had cash and cash equivalents of approximately€27 million. Based on its operating plans, Kiadis believes that it will be able to meet itsfinancing needs until February 2019. Based on its present requirements, Kiadis believes itsoperations will require cash resources of approximately €29 million to provide it with sufficientworking capital for the next twelve months following the Registration Document Date and thatthe current working capital shortfall amounts to approximately €2 million. Kiadis does notgeneratesufficientcashfromproductrevenuestomeetitscurrentworkingcapitalrequirements and is largely dependent on the issuance and sale of equity and debt securitiesto finance its operations and to proceed with the current plans for clinical development,includingforitsproductcandidatesthatprovideforAllodepletedT-cellImmunotheRapeutics (ATIR).'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> 'Netherlands'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://wikidata.org/entity/Q192907> 'consolidated financial statements '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://wikidata.org/entity/Q192907> 'consolidated financial statement'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://wikidata.org/entity/Q192907> <http://www.wikidata.org/entity/Q380559>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/OwnershipAndControl/Executives/Auditor> 'audited byKPMG Accountants N.V. (KPMG),'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://wikidata.org/entity/Q740419> 'unqualified auditors report on'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://wikidata.org/entity/Q740419> 'or the financial years ended 31 December 2016, 2015and 2014'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://wikidata.org/entity/Q192907> 'audited'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/Dividend> 'The Company has never declared or paid any dividends on its Shares.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://wikidata.org/entity/Q192907> 'the unauditedconsolidated interim financial statements'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://wikidata.org/entity/Q192907> '2017-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/AccountingFramework> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/AccountingFramework> <http://www.wikidata.org/entity/Q176831>.
_:N728e2dce270b4a6db803c6443498209e <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '34700000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N728e2dce270b4a6db803c6443498209e <https://spec.edmcouncil.org/fibo/ontology/FND/Accounting/CurrencyAmount/hasCurrency> <https://www.wikidata.org/entity/Q4916>.
_:N728e2dce270b4a6db803c6443498209e <http://www.w3.org/1999/02/22-rdf-syntax-ns#label> '(€34.7 million as gross proceeds'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://wikidata.org/entity/Q850210> _:N728e2dce270b4a6db803c6443498209e.
_:Naf51f8b7a59d4d808b1669e2435063de <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '31200000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Naf51f8b7a59d4d808b1669e2435063de <https://spec.edmcouncil.org/fibo/ontology/FND/Accounting/CurrencyAmount/hasCurrency> <https://www.wikidata.org/entity/Q4916>.
_:Naf51f8b7a59d4d808b1669e2435063de <http://www.w3.org/1999/02/22-rdf-syntax-ns#label> '€31.2 million as net proceeds'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://wikidata.org/entity/Q850210> _:Naf51f8b7a59d4d808b1669e2435063de.
<http://example.org/entity/#KiadisPharmaN.V.> <https://wikidata.org/entity/Q243460> 'Consolidated income statement'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://wikidata.org/entity/Q8148> 'The biotechnology industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://wikidata.org/entity/Q8148> <http://www.wikidata.org/entity/Q21157865>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://wikidata.org/entity/Q8148> <http://www.wikidata.org/entity/Q12303494>.
<http://example.org/entity/#KiadisPharmaN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'Kiadis is a clinical stage, biopharmaceutical company focused on research, development andfuture commercialisation of cell-based immunotherapy products as adjunctive treatment forHSCT in blood cancers and inherited blood disorders.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://wikidata.org/entity/Q963465> 'Significant unmet medical need'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Intellectual property7.14.1Strategy'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Parties/Parties/isAffectedBy> 'Introduction to Kiadis key technology – the Theralux platformced intensity conditioning '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://wikidata.org/entity/Q192907> 'As per September 30, 2017, the Group has one lead product under development beingATIR. This is considered to be the only reportable segment. All corporate activities can beassigned therefore to this segment as well. Therefore, no additional segment analysis isdisclosed.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://spec.edmcouncil.org/fibo/ontology/BP/SecuritiesIssuance/MuniIssuance/hasFinancialAdvisor> 'Simmons & Simmons LLP'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#KiadisPharmaN.V.> <https://spec.edmcouncil.org/fibo/ontology/BP/SecuritiesIssuance/MuniIssuance/hasFinancialAdvisor> <http://www.wikidata.org/entity/Q7517983>.
